Reconstructing tumor trajectories during therapy through integration of multiple measurement modalities.
Griffiths, J. I.; Chen, J.; O'Dea, A.; Sharma, P.; Winblad, O.; Trivedi, M.; Kalinsky, K.; Wisinski, K.; O'Regan, R.; Makhoul, I.; Spring, L.; Bardia, A.; Yuan, Y.; Jahanzeb, M.; Adler, F.; Cohen, A.; Bild, A.; Khan, Q.
Show abstract
BackgroundAccurately determining changes in tumor size during therapy is essential to evaluating response or progression. However, individual imaging methodologies often poorly reflect pathologic response and long-term treatment efficacy in patients with estrogen receptor positive (ER+) early-stage breast cancer. Mathematical models that measure tumor progression over time by integrating diverse imaging and tumor measurement modalities are not currently used but could increase accuracy in measuring response and provide biological insights into cancer evolution. MethodsFor ER+ breast cancer patients enrolled on a neoadjuvant clinical trial, we reconstructed their tumor size trajectories during therapy by combining all available information on tumor size, including different imaging modalities, physical examinations and pathological assessment data. Tumor trajectories during six months of treatment were generated, using a Gaussian process and the most probable trajectories were evaluated, based on clinical data, using measurement models that account for biases and differences in precision between tumor measurement methods, such as MRI, ultrasound and mammograms. ResultsReconstruction of tumor trajectories during treatment identified five distinct patterns of tumor size changes, including rebound growth not evident from any single modality. These results increase specificity to distinguish innate or acquired resistance compared to using any single measurement alone. The speed of therapeutic response and extent of subsequent rebound tumor growth quantify sensitivity or resistance in this patient population. ConclusionsTumor trajectory reconstruction integrating multiple modalities of tumor measurement accurately describes tumor progression on therapy and reveals various patterns of patient responses. Mathematical models can integrate diverse response assessments and account for biases in tumor measurement, thereby providing insights into the timing and rate at which resistance emerges.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer 95%
- Deactivation of ligand-receptor interactions enhancing lymphocyte infiltration drives melanoma resistance to Immune Checkpoint Blockade 94%
- Data-driven learning how oncogenic gene expression locally alters heterocellular networks 93%
Similar papers in this journal
- Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition 95%
- A single-cell based precision medicine approach using glioblastoma patient-specific models 92%
- Image-Based Consensus Molecular Subtyping in Rectal Cancer Biopsies and Response to Neoadjuvant Chemoradiotherapy 91%
Similar papers in this journal
- Image-Guided Targeting of Mitochondrial Metabolism Sensitizes Pediatric Malignant Rhabdoid Tumors to Low Dose Radiotherapy 93%
- Generative Adversarial Networks Accurately Reconstruct Pan-Cancer Histology from Pathologic, Genomic, and Radiographic Latent Features 92%
- Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertib 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.